Faes Farma (FAE.MC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

FAE.MC · Stock Price

EUR 4.86+0.58 (+13.42%)

Market Cap: $1.8B

Historical price data

Market Cap: $1.8BPipeline: 17 drugs (10 Phase 3)Founded: 1933Employees: 2600+HQ: Leioa, Spain

Sector Ranking#159 in Small Molecule Drugs

Overview

Faes Farma is a leading Spanish pharmaceutical group with a mission to transform health through passion, science, and innovation, achieving €627 million in revenue in 2025 with 23% year-over-year growth. Its strategy is built on a vertically integrated model, a focus on key therapeutic molecules like Bilastine and Calcifediol, and strategic acquisitions to bolster international presence and leadership in ophthalmology. The company aims to be at the forefront of excellence in health and well-being, supported by a dual business model spanning human pharmaceuticals and animal nutrition.

AllergyGastroenterologyOphthalmologyDermatologyCardiologyAnimal Nutrition

Technology Platform

Vertically integrated pharmaceutical development and manufacturing platform centered on chemical synthesis, API production, advanced formulation science, and proprietary microencapsulation technology.

Pipeline

17

17 drugs in pipeline10 in Phase 3

Drug	Indication	Stage
Bilastine + Desloratadine + Placebo	Seasonal Allergic Rhinitis	Phase 3
Hemorrane plus + Hemorrane + Placebo	Haemorrhoids Without Complication	Phase 3
Bilastine Ophthalmic Solution 0.6% + Ketotifen Ophthalmic So...	Allergic Conjunctivitis	Phase 3
Mesalazine	Colitis, Ulcerative	Phase 3
Bilastine + Placebo	Allergic Conjunctivitis	Phase 3

Funding History

1

IPOUndisclosedUndisclosedJun 15, 1995

Opportunities

Significant growth opportunities exist in the international expansion of core strategic molecules (Bilastine, Calcifediol) and the integration of the newly acquired ophthalmology portfolio, which provides immediate scale in a high-growth therapeutic area.

The vertically integrated model also offers opportunities for cost leadership and supply chain resilience in an uncertain global environment.

Risk Factors

Key risks include execution and integration challenges related to recent major acquisitions (SIFI, Edol), potential long-term dependency on a few key marketed molecules without a robust late-stage internal pipeline, and exposure to geopolitical and macroeconomic volatility across its 130+ country footprint.

Competitive Landscape

Faes Farma competes with large multinational pharma companies in allergy/OTC, generic manufacturers in gastroenterology, and established players like Alcon in ophthalmology. Its competitive moats are vertical integration, ownership of proprietary molecules like Bilastine, and deep regional expertise in Iberia and Latin America.